雷帕霉素和紫杉醇药物洗脱支架治疗冠状动脉开口病变：1年随访评价有效和安全性

Rapamycin-eluting stent versus paclitaxel-eluting stent for coronary ostial lesions: effective and safety evaluation after 1-year follow-up

BACKGROUND: Rapamycin and paclitaxel eluting stents have been widely used in the treatment of coronary ostial lesions (left main coronary artery and right coronary artery ostial lesions). However, the comparative research on the effectiveness and safety of the two stents for coronary ostial lesions is relatively rare.OBJECTIVE: To explore the efficacy and safety of the rapamycin-eluting stent versus paclitaxel-eluting stent in the treatment of coronary ostial lesions.METHODS: 135 patients with coronary ostial lesions were selected and were allotted into two groups by random number table, 73 cases treated with rapamycin-eluting stent and the remaining 62 cases treated with paclitaxel-eluting stent. After 12-month follow-up, the incidence of adverse cardiac events, thrombosis, target lesion revascularization and stent-restenosis were compared between two groups.RESULTS AND CONCLUSION: Neither did stent drop off or displace, nor did other adverse reactions related to the stent occurr in both two groups. The incidence of cardiac adverse events in the rapamycin group and paclitaxel group was 8.5% and 6.8%; the rate of thrombosis was 3.9% and 4.1%; the rate of the target lesion revascularization was 4.1% and 6.4%; the rate of stent-restenosis was 7.5% and 9.2%, respectively. All above indicators showed no significant differences between two groups. In conclusion, the efficacy and safety of the rapamycin-eluting stent for coronary ostial lesions are equivalent to those of the paclitaxel-eluting stent.